These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22313953)

  • 1. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis.
    Ajose O; Mookerjee S; Mills EJ; Boulle A; Ford N
    AIDS; 2012 May; 26(8):929-38. PubMed ID: 22313953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
    Humphreys EH; Chang LW; Harris J
    Cochrane Database Syst Rev; 2010 Jun; (6):CD006517. PubMed ID: 20556768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.
    Pujades-Rodríguez M; Balkan S; Arnould L; Brinkhof MA; Calmy A;
    JAMA; 2010 Jul; 304(3):303-12. PubMed ID: 20639564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda.
    Ndahimana Jd; Riedel DJ; Muhayimpundu R; Nsanzimana S; Niyibizi G; Mutaganzwa E; Mulindabigwi A; Baribwira C; Kiromera A; Jagodzinski LL; Peel SA; Redfield RR
    Antivir Ther; 2016; 21(3):253-9. PubMed ID: 26562173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden.
    Häggblom A; Svedhem V; Singh K; Sönnerborg A; Neogi U
    Lancet HIV; 2016 Apr; 3(4):e166-74. PubMed ID: 27036992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
    Sigaloff KC; Calis JC; Geelen SP; van Vugt M; de Wit TF
    Lancet Infect Dis; 2011 Oct; 11(10):769-79. PubMed ID: 21872531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very early virological failure and drug resistance mutations in a woman on antiretroviral therapy in Eastern Cape, South Africa: a case report.
    Sogbanmu OO; Adeniyi OV; Fuentes YO; Ter Goon D
    J Med Case Rep; 2015 May; 9():106. PubMed ID: 25947544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of HIV-infected patients receiving second-line antiretroviral therapy in a resource-limited setting in Nigeria.
    Onyedum CC; Iroezindu MO; Chukwuka CJ; Anyaene CE; Obi FI; Young EE
    Trans R Soc Trop Med Hyg; 2013 Oct; 107(10):608-14. PubMed ID: 23959002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
    Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
    Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study.
    Guiguet M; Ghosn J; Duvivier C; Meynard JL; Gras G; Partisani M; Teicher E; Mahamat A; Rodenbourg F; Launay O; Costagliola D;
    AIDS; 2012 Nov; 26(18):2345-50. PubMed ID: 22695301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
    Péré H; Charpentier C; Mbelesso P; Dandy M; Matta M; Moussa S; De Dieu Longo J; Grésenguet G; Abraham B; Bélec L
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):315-23. PubMed ID: 21942692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy].
    Brunner J; Seybold U; Gunsenheimer-Bartmeyer B; Hamouda O; Bogner JR;
    Dtsch Med Wochenschr; 2010 Jun; 135(23):1166-70. PubMed ID: 20514595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study.
    Adawaye C; Fokam J; Kamangu E; Alio HM; Chahad AM; Susin F; Moussa AM; Bertin TH; Tidjani A; Vaira D; Moutschen M
    BMC Res Notes; 2017 Nov; 10(1):589. PubMed ID: 29126456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
    Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
    Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?
    Orrell C; Cohen K; Leisegang R; Bangsberg DR; Wood R; Maartens G
    AIDS Res Ther; 2017 Apr; 14(1):20. PubMed ID: 28376815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with antiretroviral treatment failure among people living with HIV on antiretroviral therapy in resource-poor settings: a systematic review and metaanalysis.
    Lailulo Y; Kitenge M; Jaffer S; Aluko O; Nyasulu PS
    Syst Rev; 2020 Dec; 9(1):292. PubMed ID: 33308294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.